CroiValve

The DUO Adapt system offers a minimally invasive treatment option for tricuspid regurgitation, tailored to individual heart anatomy.

The DUO Adapt system provides a minimally invasive solution for severe tricuspid regurgitation, expanding treatment options for patients.

Tricuspid regurgitation is an underdiagnosed heart valve disease affecting quality of life and increasing mortality risk in older populations.

Veteran structural heart executive to lead the company through its next phase of clinical and commercial growth

CroíValve seeks qualified candidates to join its team and offers open positions for applicants.

Kelly has 20 years of experience in early-stage technology scouting, new company formation, business development, and corporate venture capital. As a Director at Broadview Ventures, Kelly focuses on new investment activity and portfolio management and leads Broadview’s MedTech practice.

Jaime has over 25 years of leadership in medical devices and pharmaceuticals, with clinical research experience in cardiology and structural heart technologies.

CroíValve develops heart valve treatments, guided by a patient-focused team with clinical, technical, and commercial expertise in heart health.

CroíValve’s office is located at Unit ALiffey Trust Enterprise Centre, 117-125 Sheriff Street Upper, Dublin, Ireland, with contact details provided.

CroíValve’s DUO Adapt system aims to address tricuspid regurgitation with a minimally invasive heart valve device.

This GDPR policy sets out how CroíValve uses and protects any personal information shared with it as a result of any interaction with the organisation. All data collected, recorded, stored, processed and destroyed will be treated in accordance with the European General Data Protection Regulation (GDPR) 2016/679. CroíValve may revise this policy from time to […]